Karyopharm to Cut About 20% of Workforce Amid Ongoing Review

Dow Jones

2025/07/11

By Connor Hart

Karyopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses.

The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission.

Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer.

The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said.

Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

July 11, 2025 08:21 ET (12:21 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550595305"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550595305\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550595305?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-11 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550595305","market":"us","top_or_hot":-1,"title":"Karyopharm to Cut About 20% of Workforce Amid Ongoing Review","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KPTI\">Karyopharm Therapeutics</a> said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n</p>\n<p>\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n</p>\n<p>\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n</p>\n<p>\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n</p>\n<p>\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm to Cut About 20% of Workforce Amid Ongoing Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm to Cut About 20% of Workforce Amid Ongoing Review\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-11 20:21</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/KPTI\">Karyopharm Therapeutics</a> said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n</p>\n<p>\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n</p>\n<p>\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n</p>\n<p>\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n</p>\n<p>\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 08:21 ET (12:21 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KPTI","symbol_name":"Karyopharm Therapeutics Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550595305","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550595305","pubTimestamp":1752236460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Karyopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses.The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission.Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer.The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said.Shares fell 16%, to $4.21, in premar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KPTI":"Karyopharm Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Karyopharm将在持续审查中裁员约20%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nKaryopharm Therapeutics said it will further reduce its workforce by approximately 20% as part of its ongoing management of operating expenses. \n\n\n  The commercial-stage pharmaceutical company had 279 employees as of Feb. 14, according to the latest headcount available in filings with the Securities and Exchange Commission. \n\n\n  Karyopharm expects one-time expenses stemming from the layoffs to be immaterial. The company said Friday that it remains committed to expanding the use of its treatment for multiple myeloma, a type of blood cancer, as well as advancing ongoing trials for its treatments of myelofibrosis and endometrial cancer. \n\n\n  The company is continuing to evaluate various alternatives to extend its cash runway, and said it engaged with potential investors to discuss potential financing transactions. It is also evaluating a potential merger or sale of the company, in- or out-of-court restructurings, and other refinancings of existing debt, the company said. \n\n\n  Shares fell 16%, to $4.21, in premarket trading. Through Thursday's close, the stock has lost nearly two-thirds of its value in the past year. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 08:21 ET (12:21 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}